Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 6,354 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Intestinal Disorders Clear all
Recruiting Phase 1Phase 2 Interventional

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

NCT04585750
View directory record Official record
Conditions
Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer, Gall Bladder Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, NSCLC, NSCLC (Non-small Cell Lung Cancer), SCLC, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, TNBC, HER2+ Breast Cancer, Non-Small Cell Lung Cancer, ER/PR Positive Breast Cancer, HER2- Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, ER/PR(+), Her2(-) Breast Cancer
Interventions
rezatapopt, pembrolizumab
Drug
Lead sponsor
PMV Pharmaceuticals, Inc
Industry
Eligibility
12 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
32
States / cities
Irvine, California • La Jolla, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 21, 2026, 6:16 AM EDT
Terminated Phase 2 Interventional Results available

Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases

NCT03844750
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions
Hepatectomy, Pembrolizumab, Vactosertib
Procedure · Biological · Drug
Lead sponsor
Chloe Atreya, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 21, 2026, 6:16 AM EDT
Completed No phase listed Observational

Combined Colon and Endometrial Cancer Screening in Women With HNPCC

NCT00510796
View directory record Official record
Conditions
Colon Cancer
Interventions
Interview
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Oct 21, 2026, 6:16 AM EDT
Completed Phase 1 Interventional Results available

A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors

NCT04672460
View directory record Official record
Conditions
Advanced Solid Tumors, Solid Tumors, Ovarian Cancer, Breast Cancer, Prostate Cancer, NSCLC, Pancreatic Cancer, Colorectal Cancer
Interventions
TALZENNA capsule, Talazoparib soft gel capsule
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
23
States / cities
Encinitas, California • Los Angeles, California • San Marcos, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2024 · Synced Oct 21, 2026, 6:16 AM EDT
Completed Phase 2 Interventional Results available

Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet

NCT04530123
View directory record Official record
Conditions
Celiac Disease
Interventions
Placebo, TAK-101, Gluten
Drug · Dietary Supplement
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
26
States / cities
Scottsdale, Arizona • Escondido, California • Poway, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 21, 2026, 6:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Dietary Green Tea Confection For Resolving Gut Permeability-Induced Metabolic Endotoxemia In Obese Adults

NCT03413735
View directory record Official record
Conditions
Obesity, Endotoxemia, Inflammation
Interventions
Green Tea Extract, Placebo
Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 13, 2025 · Synced Oct 21, 2026, 6:16 AM EDT
Withdrawn Not applicable Interventional

Feasibility Study to Develop Sentinel Lymph Node Mapping in Rectal Cancer Patients

NCT02112240
View directory record Official record
Conditions
Rectal Cancer
Interventions
Intraoperative Mobile Gamma Camera imaging, Endoscopic injection of 99mTc-sulfur colloid, Endoscopic injections of Spot, Preoperative flexible sigmoidoscopy, SPECT/CT
Other · Drug · Procedure + 1 more
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 15, 2016 · Synced Oct 21, 2026, 6:16 AM EDT
Recruiting Phase 1 Interventional

A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

NCT07503808
View directory record Official record
Conditions
Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Castration-resistant Prostate Cancer, Non Small Cell Lung Cancer, Endometrium Cancer, Triple Negative Breast Cancer
Interventions
IDE034
Drug
Lead sponsor
IDEAYA Biosciences
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
15
States / cities
Denver, Colorado • Sarasota, Florida • Detroit, Michigan + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 21, 2026, 6:16 AM EDT
Completed No phase listed Observational

Genetic Investigation of Solid Tumors Cohort

NCT01005225
View directory record Official record
Conditions
Prostate Cancer, Colon Cancer
Interventions
Not listed
Lead sponsor
Scripps Translational Science Institute
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 12, 2014 · Synced Oct 21, 2026, 6:16 AM EDT
Completed Not applicable Interventional

Comparative Study of Laparoscopic Versus Open Appendectomy in Children

NCT00554008
View directory record Official record
Conditions
Appendicitis
Interventions
laparoscopic appendectomy, open appendectomy
Procedure
Lead sponsor
Oregon Health and Science University
Other
Eligibility
Up to 18 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
3
States / cities
Los Angeles, California • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 30, 2012 · Synced Oct 21, 2026, 6:16 AM EDT
Not listed Phase 2 Interventional

International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel

NCT02051868
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Anus
Interventions
Cisplatin, 5-Fluorouracil (5-FU), Carboplatin, Paclitaxel
Drug
Lead sponsor
Royal Marsden NHS Foundation Trust
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced Oct 21, 2026, 6:16 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

CHOICE: Communicating Health Options Through Information and Cancer Education

NCT00134589
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Academic Detailing (Medical Practices)+Decision Aids (Patients)
Behavioral
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
52 Years to 75 Years
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 4, 2009 · Synced Oct 21, 2026, 6:16 AM EDT
Completed Not applicable Interventional

Mindfulness vs. Support Groups for Irritable Bowel Syndrome

NCT00680693
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Mindfulness training, Psycho-educational support group for women with IBS
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 18, 2011 · Synced Oct 21, 2026, 6:16 AM EDT
Recruiting Phase 2 Interventional

Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC

NCT06553885
View directory record Official record
Conditions
Metastatic Colorectal Cancer, Hepatocellular Carcinoma
Interventions
Enfortumab Vedotin
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 21, 2026, 6:16 AM EDT
Completed Phase 2 Interventional Results available

Molecular Targeting of 15-Lipoxygenase-1 (15-LOX-1) for Apoptosis Induction in Human Colorectal Cancers

NCT00503035
View directory record Official record
Conditions
Familial Adenomatous Polyposis
Interventions
Celecoxib, Colonoscopy Biopsy
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Oct 21, 2026, 6:16 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases

NCT02859415
View directory record Official record
Conditions
Esophageal Neoplasms, Lung Neoplasms, Mesothelioma, Thymus Neoplasms, Neoplasms, Germ Cell and Embryonal
Interventions
Mithramycin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Oct 21, 2026, 6:16 AM EDT
Completed No phase listed Observational

Comparison of Gut Microbiota, Inflammation and Symptoms Following Allogeneic HSCT

NCT02398708
View directory record Official record
Conditions
Graft vs Host Disease, Graft Versus Host Disease, Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation
Interventions
Questionnaires, Blood Sample, Stool Sample, Clinical data
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 25, 2019 · Synced Oct 21, 2026, 6:16 AM EDT
Suspended No phase listed Observational

Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery

NCT04955808
View directory record Official record
Conditions
Breast Carcinoma, Colon Carcinoma, Invasive Carcinoma, Kidney Carcinoma, Liver Carcinoma, Malignant Solid Neoplasm, Multiple Myeloma, Prostate Carcinoma
Interventions
Biospecimen Collection, Laboratory Biomarker Analysis
Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
2,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 21, 2026, 6:16 AM EDT
Completed Not applicable Interventional

Resistance Exercise and Creatine in Colorectal Cancer

NCT06420726
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Resistance Exercise
Behavioral
Lead sponsor
University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 21, 2026, 6:16 AM EDT
Completed Phase 2 Interventional

Portal Vein Embolization in Treating Patients With Liver Metastases From Primary Colorectal Cancer

NCT00028626
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
embolization therapy
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Oct 21, 2026, 6:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Impact of CLB101TM️ on Gut Health in Healthy, Overweight Individuals

NCT07336615
View directory record Official record
Conditions
Gastrointestinal, Overweight , Obesity
Interventions
CLB101™️, Placebo, Placebo control
Dietary Supplement · Other
Lead sponsor
ClostraBio Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 21, 2026, 6:16 AM EDT
Recruiting No phase listed Observational

The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors

NCT05037825
View directory record Official record
Conditions
Non-Small-Cell Lung Carcinoma, Malignant Melanoma, Renal Cell Carcinoma, Triple-Negative Breast Cancer
Interventions
Checkpoint Inhibitor, Immune
Drug
Lead sponsor
VastBiome
Industry
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Elizabethtown, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced Oct 21, 2026, 6:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose-Effect of S-Tenatoprazole-Na(STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers

NCT00284908
View directory record Official record
Conditions
Esophagitis, Gastroesophageal Reflux, Stomach Ulcer, Duodenal Ulcer
Interventions
S-Tenatoprazole-Na (STU-Na)
Drug
Lead sponsor
STEBA France
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2008 · Synced Oct 21, 2026, 6:16 AM EDT
Recruiting No phase listed Observational

Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC

NCT04528355
View directory record Official record
Conditions
Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD), Hereditary Anemias, Inflammatory Conditions
Interventions
data collection
Drug
Lead sponsor
Paul Szabolcs
Other
Eligibility
2 Months to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 21, 2026, 6:16 AM EDT